Seattle Genetics, Inc. (NASDAQ:SGEN) COO Eric Dobmeier sold 25,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $52.24, for a total transaction of $1,306,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Eric Dobmeier also recently made the following trade(s):

  • On Monday, August 28th, Eric Dobmeier sold 5,343 shares of Seattle Genetics stock. The stock was sold at an average price of $47.89, for a total transaction of $255,876.27.

Seattle Genetics, Inc. (NASDAQ SGEN) opened at 51.90 on Thursday. The company has a 50-day moving average of $49.79 and a 200 day moving average of $59.65. Seattle Genetics, Inc. has a 52 week low of $45.31 and a 52 week high of $75.36. The company’s market cap is $7.42 billion.

Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.03. The firm had revenue of $108.20 million during the quarter, compared to analyst estimates of $105.92 million. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. The business’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.23) EPS. On average, equities analysts forecast that Seattle Genetics, Inc. will post ($1.69) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/09/07/eric-dobmeier-sells-25000-shares-of-seattle-genetics-inc-sgen-stock.html.

A number of analysts have recently weighed in on SGEN shares. ValuEngine raised shares of Seattle Genetics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Seattle Genetics in a report on Saturday, June 3rd. Cowen and Company set a $61.00 price target on shares of Seattle Genetics and gave the stock a “hold” rating in a report on Tuesday, June 6th. J P Morgan Chase & Co reaffirmed a “hold” rating and set a $58.00 price target on shares of Seattle Genetics in a report on Tuesday, June 13th. Finally, Cann reaffirmed a “hold” rating on shares of Seattle Genetics in a report on Monday, June 19th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $62.29.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Neuberger Berman Group LLC lifted its holdings in shares of Seattle Genetics by 0.5% in the 1st quarter. Neuberger Berman Group LLC now owns 12,630 shares of the biotechnology company’s stock worth $794,000 after acquiring an additional 59 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of Seattle Genetics by 0.3% in the 2nd quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock worth $1,640,000 after acquiring an additional 91 shares during the last quarter. Eqis Capital Management Inc. lifted its holdings in shares of Seattle Genetics by 0.7% in the 2nd quarter. Eqis Capital Management Inc. now owns 26,258 shares of the biotechnology company’s stock worth $1,359,000 after acquiring an additional 177 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Seattle Genetics by 1.2% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,613 shares of the biotechnology company’s stock worth $981,000 after acquiring an additional 191 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its holdings in shares of Seattle Genetics by 1.1% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 18,400 shares of the biotechnology company’s stock worth $952,000 after acquiring an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.